SARMs (Selective Androgen Receptor Modulators) are increasingly progressing through clinical trials for oncological indications, particularly ostarine (MK-2866, rebranded as Enobosarm) for triple-negative androgen receptor-positive breast cancer and prostate cancer, where they inhibit the adrenal androgen synthesis cascade without the systemic virilization of exogenous testosterone.